Key result
CAAN-AF trial investigates CRT with or without AV node ablation in AF.
Why the study?
Patients with HFrEF derive less benefit from CRT if they have coexisting AF, and observational data suggesting AV node ablation may enhance CRT efficacy required evaluation in a randomized trial.
Population
143 patients with HFrEF, permanent AF, and CRT-D
Comparison
AV node ablation vs medical rate control therapy
Design
International, prospective, multicentre, randomized controlled trial
Answers are grounded in this paper and cite their sources.
This trial evaluates AV node ablation in heart failure patients with atrial fibrillation, showing no significant outcome differences.
Background and Aims Patients with heart failure with reduced ejection fraction (HFrEF) derive less benefit from cardiac resynchronization therapy (CRT) if they have coexisting atrial fibrillation (AF). Observational data suggest that atrioventricular node ablation (AVNA) may enhance CRT efficacy in this population. This trial aimed to evaluate the effect of AVNA compared with medical rate control therapy (MRCT) on CRT outcomes in patients with HFrEF and permanent AF. Methods The CAAN-AF trial was an international, prospective, multicentre, randomized controlled trial evaluating the impact of AVNA in patients with HFrEF, permanent AF, and CRT-defibrillators (CRT-D). Participants were randomly assigned (1:1) to AVNA or MRCT targeting a resting heart rate <90 bpm. All participants received device optimization. The primary endpoint was a composite of all-cause mortality and nonfatal heart failure events. Secondary endpoints included cardiovascular mortality, unplanned hospitalizations, ventricular arrhythmias requiring device therapy, 6-min walk distance (6MWD), and quality of life. Results With early termination of the trial due to futility, a total of 143 patients were randomized (67 to AVNA, 76 to MRCT). Baseline characteristics were similar across groups. No significant difference was found in the primary endpoint [47 vs. 46 events; incident rate ratio (IRR), 1.16; 95% confidence interval (CI), 0.60–2.24]. Secondary outcomes, including cardiovascular mortality (odds ratio, 1.93; 95% CI 0.60–6.20), unplanned hospitalizations (IRR, 1.01; 95% CI 0.71–1.74), ventricular arrhythmias requiring device therapy (IRR, 0.68; 95% CI 0.17–2.63), 6MWD, and SF-36 scores, also showed no significant differences. Conclusions This randomized trial of patients with permanent AF and CRT-D found no evidence of a reduction in all-cause mortality and nonfatal heart failure events with AVNA compared with MRCT. Trial Registration NCT01522898.
No takes yet. Share an insight, caveat, or question.
Sanders et al. (2026) studied this question. Cardiac resynchronization therapy with or without atrioventricular node ablation in atrial fibrillation is the focus of the CAAN-AF trial (NCT01522898).
Synapse has enriched 10 related papers. Consider them for comparative context: